A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...

Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

Sermorelin.com Introduces Physician-Led Telehealth for Sermorelin Treatment Sheridan, United States - March 15, 2026 / ...

Researchers analyzed nearly 8,000 patients stopping semaglutide or tirzepatide. Most patients maintained weight or continued losing weight after one year, often by restarting therapy, switching ...

GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides ...

UAB researchers report that the oral drug TIX100 prevented weight regain after stopping semaglutide in preclinical studies.

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24.

Sermorelin.com, a telehealth platform specializing in physician-supervised peptide therapy, today announced the launch of a new clinical program designed to help patients on GLP-1 receptor agonist ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

(Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engineered probiotic candidate being developed by its wholly owned subsidiary, NorthStrive ...

GLP-1 receptor agonists have gained attention as medications to manage type 2 diabetes and obesity. Drugs such as semaglutide and tirzepatide help regulate blood sugar and reduce appetite, which can ...